During a median follow-up of 3.8 years (2.6–4.8), patients with TRH were more likely to experience the composite outcomes of death, MI, HF, stroke, or CKD, compared with those with non-TRH (18.0% vs 13.5%, P = 0.001; HR, 1.54; 95% CI, 1.40–1.69). The gene discussed is TRH; the disease is Stroke.